HELIX DIAGNOSTICS
Pharmacogenomics (PGx) Cardiovascular Panel
Panel Description
Many medications used to treat cardiovascular conditions are impacted by specific variations in known genes. These genetic variations can contribute to medication efficacy and risk for side effects. Pharmacogenomic testing to guide prescribing, paired with clinical monitoring can impact outcomes for patients by reducing the time to therapeutic effect and reducing the risk of side effects.
This panel evaluates 11 genes associated with response to drugs prescribed to treat cardiovascular disease, including anticoagulants, antiarrhythmics, antihypertensives, antiplatelets, beta blockers, and HMG-CoA Reductase Inhibitors (statins). Results from this test may help in predicting treatment efficacy and risk of side effects for these drugs.
Genes Tested (11)
Important Panel Information
Turnaround time: 7-10 days
Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
This test utilizes next-generation sequencing to determine results for ABCB1, ABCG2, CYP2C cluster, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP4F2, GRK4, SLCO1B1, and VKORC1. These results are used to determine drug considerations for the following drugs: Atorvastatin, Clopidogrel, Flecainide, Fluvastatin, Lovastatin, Metoprolol, Pitavastatin, Pravastatin, Propafenone, Rosuvastatin, Simvastatin, Warfarin.
Additionally, due to lack of sufficient scientific evidence, genetic outcomes are provided without drug considerations for the following drugs: Atenolol, Carvedilol, Digoxin, Losartan, Nebivolol, Propranolol, Quinidine, Timolol.
All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.